Welcome to the UPF Digital Repository

Profile of clinical and analytical parameters in bronchiectasis patients during the COVID-19 pandemic: a one-year follow-up pilot study

Show simple item record

dc.contributor.author Qin, Liyun
dc.contributor.author Gonçalves-Carvalho, Filipe
dc.contributor.author Xia, Yingchen
dc.contributor.author Zha, Jianhua
dc.contributor.author Admetlló Papiol, Mireia
dc.contributor.author Maiques LLacer, José María
dc.contributor.author Esteban-Cucó, Sandra
dc.contributor.author Duran Jordà, Xavier, 1974-
dc.contributor.author Marín, Alicia
dc.contributor.author Barreiro Portela, Esther
dc.date.accessioned 2022-09-30T05:51:34Z
dc.date.available 2022-09-30T05:51:34Z
dc.date.issued 2022
dc.identifier.citation Qin L, Gonçalves-Carvalho F, Xia Y, Zha J, Admetlló M, Maiques JM, Esteban-Cucó S, Duran X, Marín A, Barreiro E. Profile of clinical and analytical parameters in bronchiectasis patients during the COVID-19 pandemic: a one-year follow-up pilot study. J Clin Med. 2022 Mar 21;11(6):1727. DOI: 10.3390/jcm11061727
dc.identifier.issn 2077-0383
dc.identifier.uri http://hdl.handle.net/10230/54232
dc.description.abstract Whether the COVID-19 pandemic may have modified the clinical planning and course in bronchiectasis patients remains to be fully elucidated. We hypothesized that the COVID-19 pandemic may have influenced the management and clinical outcomes of bronchiectasis patients who were followed up for 12 months. In bronchiectasis patients (n = 30, 23 females, 66 years), lung function testing, disease severity [FEV1, age, colonization, radiological extension, dyspnea (FACED), exacerbation (EFACED)] and dyspnea scores, exacerbation numbers and hospitalizations, body composition, sputum microbiology, and blood analytical biomarkers were determined at baseline and after a one-year follow-up. Compared to baseline (n = 27, three patients dropped out), in bronchiectasis patients, a significant increase in FACED and EFACED scores, number of exacerbations, and erythrocyte sedimentation rate (ESR) was observed, while FEV1, ceruloplasmin, IgE, IgG, IgG aspergillus, IgM, and IgA significantly decreased. Patients presenting colonization by Pseudomonas aeruginosa (PA) remained unchanged (27%) during follow-up. In bronchiectasis patients, FEV1 declined only after a one-year follow-up along with increased exacerbation numbers and disease severity scores, but not hospitalizations. However, a significant decrease in acute phase-reactants and immunoglobulins was observed at the one-year follow-up compared to baseline. Despite the relatively small cohort, the reported findings suggest that lung function impairment may not rely entirely on the patients' inflammatory status.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher MDPI
dc.relation.ispartof J Clin Med. 2022 Mar 21;11(6):1727
dc.rights © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.title Profile of clinical and analytical parameters in bronchiectasis patients during the COVID-19 pandemic: a one-year follow-up pilot study
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3390/jcm11061727
dc.subject.keyword Immunoglobulins
dc.subject.keyword Lung function
dc.subject.keyword Non-cystic fibrosis bronchiectasis
dc.subject.keyword Nutritional status
dc.subject.keyword One-year follow-up
dc.subject.keyword Severity scores
dc.subject.keyword Systemic inflammation
dc.subject.keyword Immunoglobulins
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking